
ATAI Stock Forecast & Price Target
ATAI Analyst Ratings
Bulls say
AtaiBeckley is emerging as a significant player in the mental health therapeutics space, with a promising pipeline that includes BPL-003, VLS-01, and EMP-01 in various stages of development. The company has a strong focus on addressing the unmet needs of patients with treatment-resistant depression and social anxiety disorder. Despite some risks associated with the development of new psychiatric treatments, AtaiBeckley's innovative approach and potential for commercial success make it a compelling stock to watch.
Bears say
AtaiBeckley is facing a negative outlook due to their clinical trial results, as their Phase 3 trial for BPL-003 did not meet its primary endpoint, and their upcoming Phase 2 trial for VLS-01 is still in the early stages. While the company has seen positive Phase 2 data for EMP-01, the lack of significant pipeline advancements and the high cost of license fees and milestones suggest a potential struggle in commercialization and revenue generation in the future.
This aggregate rating is based on analysts' research of Atai Life Sciences BV and is not a guaranteed prediction by Public.com or investment advice.
ATAI Analyst Forecast & Price Prediction
Start investing in ATAI
Order type
Buy in
Order amount
Est. shares
0 shares